Get the Stockscreener App
1.66
1.76%
-0.04
In 8 Bio Inc stock is traded at $1.66, with a volume of 55,307.
It is down -1.76% in the last 24 hours and down -23.04% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$1.70
Open:
$1.67
24h Volume:
55,307
Relative Volume:
0.82
Market Cap:
$7.54M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-2.2133
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
+0.60%
1M Performance:
-23.04%
6M Performance:
-65.21%
1Y Performance:
-82.42%
1-Day Range:
$1.65
$1.77
1-Week Range:
$1.5301
$1.89
52-Week Range:
$1.5301
$12.53
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.66 | 7.88M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.34 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
695.53 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.76 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
894.00 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
370.50 | 41.77B | 4.56B | -176.77M | 225.30M | -1.7177 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
[8-K] Instil Bio, Inc. Reports Material Event | TIL SEC FilingForm 8-K - Stock Titan
[8-K] Annovis Bio, Inc. Reports Material Event | ANVS SEC FilingForm 8-K - Stock Titan
[S-8] PALISADE BIO, INC. Employee Benefit Plan Registration | PALI SEC FilingForm S-8 - Stock Titan
[8-K] KALA BIO, Inc. Reports Material Event | KALA SEC FilingForm 8-K - Stock Titan
Inmune Bio, Inc. Announces Key Developments in Clinical Programs - TradingView
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
[8-K] Passage BIO, Inc. Reports Material Event | PASG SEC FilingForm 8-K - Stock Titan
[8-K] Cabaletta Bio, Inc. Reports Material Event | CABA SEC FilingForm 8-K - Stock Titan
Belite Bio Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
KALA BIO Inc expected to post a loss of $1.45 a shareEarnings Preview - TradingView
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire Inc.
[8-K] Climb Bio, Inc. Reports Material Event | CLYM SEC FilingForm 8-K - Stock Titan
[8-K] Gossamer Bio, Inc. Reports Material Event | GOSS SEC FilingForm 8-K - Stock Titan
Gossamer Bio Inc reports results for the quarter ended September 30Earnings Summary - TradingView
[PRE 14A] Adicet Bio, Inc. Preliminary Proxy Statement - Stock Titan
[8-K] Adicet Bio, Inc. Reports Material Event | ACET SEC FilingForm 8-K - Stock Titan
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
TELA Bio to Announce Third Quarter 2025 Financial Results - GlobeNewswire
Cabaletta Bio (Nasdaq: CABA) offers webcasts across Nov–Dec conferences; 30-day replays - Stock Titan
Gossamer Bio Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
[Form 4] TELA Bio, Inc. Insider Trading Activity - Stock Titan
[Form 3] TELA Bio, Inc. Initial Statement of Beneficial Ownership - Stock Titan
[8-K] TELA Bio, Inc. Reports Material Event | TELA SEC FilingForm 8-K - Stock Titan
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 85.8% in October - Defense World
[8-K] Protagenic Therapeutics, Inc.new Reports Material Event | PTIX SEC FilingForm 8-K - Stock Titan
Cabaletta Bio, Inc. Updates on Rese-cel Clinical Trials and FDA Alignment - TradingView
ANVS prices registered direct; directors buy 1.07M shares at $2.05 - Stock Titan
INMB to discuss Q3 2025 results on Oct 30, 4:30 p.m. ET - Stock Titan
Tourmaline Bio Announces Board and Executive Resignations Following Merger - TradingView
[8-K] Tourmaline Bio, Inc. Reports Material Event | TRML SEC FilingForm 8-K - Stock Titan
Why Nuvation Bio Inc. stock is a must watch in 2025Trade Entry Report & Long-Term Safe Investment Ideas - fcp.pa.gov.br
Cabaletta Bio, Inc. Presents Clinical Data and Updates at ACR Convergence 2025 - TradingView
INmune Bio (NASDAQ: INMB) schedules results call for 4:30 PM ET on Oct 30 - Stock Titan
[8-K] PALISADE BIO, INC. Reports Material Event | PALI SEC FilingForm 8-K - Stock Titan
Q32 Bio Inc Completes Enrollment in SIGNAL-AA Phase 2a Trial - TradingView
[8-K] bioAffinity Technologies, Inc. Reports Material Event | BIAF SEC FilingForm 8-K - Stock Titan
PALI annual meeting: directors elected, auditor ratified, split approved - Stock Titan
Stop Loss: Why Nuvation Bio Inc. stock is popular among millennials2025 Sector Review & Breakout Confirmation Alerts - Trung tâm Dự báo KTTV quốc gia
Samsung to invest $110 mn in Grail to bring early-cancer test to Asia - KED Global
Climb Bio Publishes Long-Term Data on Budoprutug - TradingView
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 - Stock Titan
CLYM reports budoprutug Phase 1b follow-up: 3-year control in 4 pts - Stock Titan
Palisade Bio Provides Corporate and Compliance Update - TradingView
PALI back in Nasdaq bid-price compliance; 133.0M shares out - Stock Titan
ANVS prices $6.0M offering; adds pre-funded and agent warrants - Stock Titan
[8-K] – Inmune Bio, Inc. (INMB) (CIK 0001711754) - Stock Titan
Inmune Bio Inc Announces Participation in Dermatologic Panel - TradingView
Oct 22 CEO Panel: INmune Bio's CORDStrom for RDEB — David Moss at Maxim Growth Summit in NYC - Stock Titan
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewswire
Is Mustang Bio Inc. stock ready for a breakoutJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
OrbiMed Funds Buy into Adicet Bio Offering; Ownership Diluted to 9.6% - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
In 8 Bio Inc Stock (INAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCall Patrick | CHIEF FINANCIAL OFFICER |
Apr 30 '25 |
Option Exercise |
0.18 |
15,000 |
2,766 |
67,071 |
| Roemer Alan S. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
113,459 |
20,922 |
398,489 |
| Brandt Peter C. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
163,934 |
30,229 |
681,538 |
0.16%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):